Primum non nocere—first, do no harm with bariatric surgery

Karl J. Neff; Carel W. le Roux

doi:10.1016/S2213-8587(21)00143-1

Primum non nocere—first, do no harm with bariatric surgery

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	476-477
Number of pages	2
Journal	The Lancet Diabetes and Endocrinology
Volume	9
Issue number	8
DOIs	https://doi.org/10.1016/S2213-8587(21)00143-1
Publication status	Published (in print/issue) - Aug 2021

Bibliographical note

Funding Information:
CWlR serves on advisory boards for Novo Nordisk, Johnson & Johnson, and Herbalife; has received grant funding (to his institution) from the Irish Research Council, the Science Foundation Ireland, the Innovative Medicines Initiative of the EU, and the Health Research Board Ireland; has received honoraria, or payments for lectures, speakers bureaus, presentations, or education events, from Novo Nordisk, Johnson & Johnson, and Herbalife; has received financial support for attendance at educational events or travel from Novo Nordisk, Johnson & Johnson, and Herbalife; and is a board member of the Irish Society for Nutrition and Metabolism. KJN declares no competing interests.

Keywords

Bariatric Surgery/adverse effects
Humans

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-8587(21)00143-1

Cite this

@article{c9e3a53fc31945c6b67b1d93606a8b02,

title = "Primum non nocere—first, do no harm with bariatric surgery",

keywords = "Bariatric Surgery/adverse effects, Humans",

author = "Neff, {Karl J.} and {le Roux}, {Carel W.}",

note = "Funding Information: CWlR serves on advisory boards for Novo Nordisk, Johnson & Johnson, and Herbalife; has received grant funding (to his institution) from the Irish Research Council, the Science Foundation Ireland, the Innovative Medicines Initiative of the EU, and the Health Research Board Ireland; has received honoraria, or payments for lectures, speakers bureaus, presentations, or education events, from Novo Nordisk, Johnson & Johnson, and Herbalife; has received financial support for attendance at educational events or travel from Novo Nordisk, Johnson & Johnson, and Herbalife; and is a board member of the Irish Society for Nutrition and Metabolism. KJN declares no competing interests.",

year = "2021",

month = aug,

doi = "10.1016/S2213-8587(21)00143-1",

language = "English",

volume = "9",

pages = "476--477",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier BV",

number = "8",

}

TY - JOUR

T1 - Primum non nocere—first, do no harm with bariatric surgery

AU - Neff, Karl J.

AU - le Roux, Carel W.

N1 - Funding Information: CWlR serves on advisory boards for Novo Nordisk, Johnson & Johnson, and Herbalife; has received grant funding (to his institution) from the Irish Research Council, the Science Foundation Ireland, the Innovative Medicines Initiative of the EU, and the Health Research Board Ireland; has received honoraria, or payments for lectures, speakers bureaus, presentations, or education events, from Novo Nordisk, Johnson & Johnson, and Herbalife; has received financial support for attendance at educational events or travel from Novo Nordisk, Johnson & Johnson, and Herbalife; and is a board member of the Irish Society for Nutrition and Metabolism. KJN declares no competing interests.

PY - 2021/8

Y1 - 2021/8

KW - Bariatric Surgery/adverse effects

KW - Humans

UR - http://www.scopus.com/inward/record.url?scp=85110570522&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(21)00143-1

DO - 10.1016/S2213-8587(21)00143-1

M3 - Comment/debate

C2 - 34217406

AN - SCOPUS:85110570522

VL - 9

SP - 476

EP - 477

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

SN - 2213-8587

IS - 8

ER -

Primum non nocere—first, do no harm with bariatric surgery

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Cite this